在达沃斯世界经济论坛期间，德勤中国首席执行官刘明华在接受第一财经记者采访时表示，中国企业出 海空间广阔，但同时需应对品牌建设、本地化融合、风险主动管控等挑战，出海地区和方式也有新变 化。谈及未来3到5年最可能成功的行业时，刘明华认为，AI、新药研发、能源转型等新兴产业有较大 机会。 在达沃斯世界经济论坛期间，德勤中国首席执行官刘明华在接受第一财经记者采访时表示，中国企业出 海空间广阔，但同时需应对品牌建设、本地化融合、风险主动管控等挑战，出海地区和方式也有新变 化。谈及未来3到5年最可能成功的行业时，刘明华认为，AI、新药研发、能源转型等新兴产业有较大 机会。 ...

Core Viewpoint - The article highlights the significant stock performance of Pop Mart, which surged over 9% due to share buybacks and positive analyst ratings from Morgan Stanley, while also noting the approval of a new drug clinical trial by Heng Rui Pharmaceutical [5][12]. Group 1: Pop Mart Stock Performance - Pop Mart experienced a notable increase of 9.07%, closing at HKD 197.20 per share, with a peak increase of 10.40% during the trading day [6][5]. - The company repurchased 1.4 million shares on January 19, spending HKD 251 million, which contributed to the stock's upward momentum [9][11]. - Morgan Stanley's report projected Pop Mart's net profit for 2025 to be RMB 12.6 billion, indicating strong financial resources for shareholder returns [11]. Group 2: Heng Rui Pharmaceutical Developments - Heng Rui Pharmaceutical received approval for the clinical trial of its drug HRS-2141, aimed at treating type 2 diabetes, marking a significant step in its drug development pipeline [13][17]. - The company has invested approximately RMB 5.4 million in the development of HRS-2141, which is currently in the early stages of clinical trials [17]. - Despite the positive news regarding the drug approval, Heng Rui's stock fell by 4.36% to HKD 73.55 per share on January 20, reflecting market volatility [18].

Group 1 - The core point of the news is that Pop Mart's stock surged over 9% due to a share buyback and positive outlook from Morgan Stanley, while the overall Hong Kong market experienced a decline [1][5][6] - Pop Mart's share price increased by 9.07%, closing at HKD 197.20 per share, with a trading volume of HKD 58.79 billion, ranking fourth among Hang Seng Index constituents [5][6] - The company repurchased 1.4 million shares on January 19 at a total cost of HKD 251 million, with plans to cancel the repurchased shares [5][6] Group 2 - Morgan Stanley's report predicts Pop Mart's net profit for 2025 to be RMB 12.6 billion, with an expected cash reserve of RMB 20 billion by the end of 2025, indicating strong financial resources for shareholder returns [6] - Heng Rui Medicine announced the approval of clinical trials for its new drug HRS-2141, aimed at treating type 2 diabetes, marking a significant step in its drug development pipeline [7][10] - The drug HRS-2141 is a fixed-dose combination formulation, with no similar drugs approved in the domestic and international markets, and the company has invested approximately RMB 5.4 million in its development so far [10][11]

Core Viewpoint - The company, Kaiyin Technology, has voluntarily withdrawn its drug registration application for Pegylated Interferon α-2 Injection (new hepatitis B indication) as approved by the National Medical Products Administration, and plans to resubmit after further clinical case studies [1] Group 1: Company Actions - The company received a termination notice for its drug registration application from the National Medical Products Administration [1] - The company will fully recognize asset impairment related to the project, reducing the total profit for 2025 by 111.3011 million yuan [1] - The withdrawal of the application will not affect existing product sales but will impact the operating performance for 2025 [1] Group 2: Industry Context - The company emphasizes the uncertainty associated with new drug development, urging investors to be aware of investment risks [1]

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 0.52% on January 19, 2025, underperforming the CSI 300 index by 0.57 percentage points, ranking 28th among 31 sub-industries [4]. - Notable performers within the pharmaceutical sub-industries included offline pharmacies (+2.39%) and blood products (+0.11%), while sectors such as medical R&D outsourcing (-1.77%) and vaccines (-1.10%) lagged behind [4]. - Takeda's new drug Oveporexton has received acceptance for its market application in China, targeting narcolepsy type 1 (NT1) and showing promising results in clinical trials [5]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceuticals: Neutral [3]

（文章来源：证券日报） 证券日报网讯 1月19日，海普瑞在互动平台回答投资者提问时表示，公司以患者临床未满足的需求为 始，通过多种研发模式布局了高度创新的临床管线，并正在积极推进各项新药开发进程。新药研发具有 周期长、投入大、风险高的特点，临床过程和结果存在诸多不确定性，如有重大进展，公司将及时履行 信息披露义务。 ...

Summary of Conference Call Records Industry Overview - The conference call primarily discusses the biopharmaceutical industry, focusing on several key companies and their projected performance for 2025 and beyond. The overall sentiment reflects a robust growth trajectory within the sector. Key Companies and Their Projections 1. WuXi AppTec (药明康德) - Expected revenue for 2025 is 454.56 billion CNY, a year-on-year increase of 15.84% - Adjusted net profit is projected to be 149.57 billion CNY, up 41.33%, with total net profit reaching 191.51 billion CNY, a 102.65% increase [2] - The company has 24 GLP-1 drug candidates, with 15 in Phase II and III clinical trials, indicating strong pipeline growth [4] 2. Kanglong Chemical (康龙化成) - Anticipates revenue between 138.72 billion CNY and 142.4 billion CNY, reflecting a growth of 13%-16% - Adjusted net profit is expected to be between 17.68 billion CNY and 18.48 billion CNY, a growth of 10%-15% [2] 3. Sunway Pharma (阳光诺和) - Projected revenue between 1.192 billion CNY and 1.37 billion CNY, a growth of 10.57%-27.15% - Expected net profit between 190 million CNY and 229 million CNY, a growth of 7.69%-29.23% [2] 4. AstraZeneca (阿斯利康) - Focused on cardiovascular, ADC, next-generation IO, and cell therapy TCE areas - Key clinical data readouts expected in 2026, which may impact market dynamics [5] 5. Gilead Sciences (吉利德) - Key projects include Cloud Native Top two ADC, expected to show promising data in TNBC treatment and potential approval in the second half of the year [8] - Anticipates significant changes in the first-line triple-negative breast cancer market due to the SG molecule [8] 6. DZD Pharma (迪哲医药) - DZD6,008 shows significant efficacy in non-small cell lung cancer (NSCLC) with an ORR of 60% and PFS exceeding 10 months [3][16] Clinical Trials and Data Readouts - Multiple companies, including Gilead, AstraZeneca, and others, are set to release important clinical trial data in 2026, which could reshape competitive dynamics in the NSCLC market [16] - AstraZeneca's ADC project 18.2 is expected to have significant clinical data readouts in 2026, with a focus on large-scale Phase III trials [7] Strategic Collaborations and Market Expansion - WuXi Biologics (药明生物) has signed a strategic cooperation memorandum with Qatar Free Zone Authority to expand into the Middle East market [4] - The conference highlighted the increasing participation of Chinese companies in the global pharmaceutical market, particularly in the dual-antibody and ADC sectors [22] Emerging Trends and Innovations - The industry is witnessing a shift towards L2.0 and ADC combinations, which are expected to become the next wave of drug development [17][18] - The importance of speed and mechanism synergy in new drug development was emphasized, indicating that early-stage projects have a higher success rate [18] Conclusion - The biopharmaceutical industry is poised for significant growth, with several companies reporting strong projections and innovative clinical developments. The upcoming clinical data releases in 2026 are anticipated to have a substantial impact on market dynamics and competitive positioning within the sector.

Core Viewpoint - The company has signed an exclusive licensing agreement with AbbVie for the PD-1/VEGF dual antibody drug RC148, granting AbbVie exclusive rights for development, production, and commercialization outside Greater China, with an upfront payment of $650 million and potential milestone payments up to $4.95 billion, along with double-digit royalties on net sales outside Greater China [1][2]. Group 1: Licensing Agreement Details - The agreement includes an upfront payment of $650 million and milestone payments that could reach up to $4.95 billion [1]. - AbbVie will have exclusive rights to develop, produce, and commercialize RC148 outside of Greater China [1]. Group 2: Clinical Data and Efficacy - RC148 has shown promising efficacy and safety in recent clinical trials, with a Phase 1 study demonstrating an overall response rate (ORR) of 61.9% and a disease control rate (DCR) of 100% among PD-L1 positive NSCLC patients [1]. - In the Phase 2 study, the combination of RC148 with docetaxel achieved an ORR of 66.7% and a DCR of 95.2%, with an ORR of 80% in PD-L1 positive patients [2]. Group 3: Business Development and Financial Impact - This licensing agreement marks the fourth successful business development (BD) transaction for the company, validating its R&D capabilities and recognition by foreign entities [2]. - The high upfront payment is expected to significantly improve the company's cash flow and provides strong financial and brand endorsement for future R&D and pipeline advancement [2]. Group 4: Profit Forecast - The company anticipates a net profit of -885 million, -449 million, and 373 million yuan for the years 2025 to 2027, with corresponding earnings per share (EPS) of -1.57, -0.80, and 0.66 yuan [2].

Core Viewpoint - East China Pharmaceutical (000963.SZ) announced that its subsidiary, Zhejiang Daor Biotechnology Co., Ltd. (referred to as "Daor Bio"), has received notification from the U.S. Food and Drug Administration (FDA) that its clinical trial application for the drug DR10624 injection has been approved, allowing clinical trials to be conducted in the U.S. for the indication of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [1] Group 1 - East China Pharmaceutical's subsidiary Daor Bio has received FDA approval for clinical trials of DR10624 injection [1] - The approved indication for the clinical trial is Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [1]

Core Viewpoint - On December 31, the company announced a deep global collaboration with AbbVie regarding ZG006, with an upfront payment of $100 million and a total deal value of $1.235 billion. The initial clinical data presented at the ESMO Asia conference showed excellent clinical response rates and good durability in SCLC indications, indicating that this collaboration may accelerate ZG006's advancement in overseas oncology indications and maximize the value of the product pipeline, suggesting a promising future for the company [1][3]. Group 1: Collaboration Details - The company has entered into a global strategic collaboration and licensing option agreement with AbbVie for the development and commercialization rights of ZG006, receiving an upfront payment of $100 million, with potential milestone payments based on clinical progress and licensing options totaling up to $60 million. If AbbVie exercises the licensing option, the company could receive up to $1.075 billion in milestone payments [2][3]. Group 2: Clinical Data and Product Pipeline - ZG006 has shown promising early clinical data in small cell lung cancer (SCLC) at the ESMO Asia conference, with overall response rates (ORR) of 60.0% and 66.7% for the 10 mg Q2W and 30 mg Q2W groups, respectively. The confirmed response rates were 53.3% and 56.7%, with disease control rates (DCR) of 73.3% for both groups. The median progression-free survival (mPFS) was 7.03 months and 5.59 months, while the median duration of response (mDoR) rates at 6 months were 71.8% and 69.5% [4]. Group 3: Commercialization Progress - The company has made breakthroughs in commercialization, with the JAK inhibitor, Jika Xini, expected to be approved by the National Medical Products Administration in May 2025, becoming the first domestically approved JAK inhibitor for treating high-risk myelofibrosis. The product has shown rapid sales growth since its launch in June and has been included in the CSCO guidelines [5]. - The recombinant human thrombin injection is set to launch in 2024, with significant efficacy demonstrated in clinical trials, and is expected to become a core growth driver for revenue [5]. Group 4: Future Catalysts - The company has a clear timeline for key catalysts in 2026, including the continued rollout of insurance policies for the recombinant thrombin and Jika Xini, which are expected to drive sales growth. Additionally, further clinical data for ZG005 and ZG006 is anticipated, along with the ongoing collaboration with AbbVie to advance overseas clinical trials [8]. Group 5: Financial Projections - The company’s revenue projections for 2025-2027 are estimated at 712 million, 1.54 billion, and 2.5 billion yuan, with net profits of -127 million, -77 million, and 147 million yuan, respectively, maintaining a "buy" rating [9].